Skip to content
Back to MDGL

Madrigal Pharmaceuticals, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
183
Purchases
5
Sales
178
Purchase value
$35.02M
Sale value
$69.43M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Shannon T KelleyGeneral Counsel
4Rule 10b5-1 plan disclosed
Filed Nov 6, 2026Period of report Nov 6, 20260001628280-26-071744
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 6, 2026
Common StockF11,077$400.00$430.80K10,397Direct
Filing footnotes · 1
  1. F1This sale was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2026.
Open on SEC EDGAR
L.P. 667Director
Bros. Advisors (GP) LLC BakerDirector
Bros. Advisors LP BakerDirector
Brothers Life Sciences LP BakerDirector
Felix BakerDirector
Julian BakerDirector
4
Filed Nov 6, 2026Period of report Nov 4, 20260001193125-26-452132
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 6, 2026
Common StockF2F3F4F6F7F860,400$383.015$23.13M2,024,942IndirectSee Footnotes
PurchaseNov 6, 2026
Common StockF2F3F4F6F7F813,740$388.29$5.34M2,038,682IndirectSee Footnotes
PurchaseNov 6, 2026
Common StockF2F3F4F6F7F82,000$396.61$793.22K2,040,682IndirectSee Footnotes
PurchaseNov 4, 2026
Common StockF5F2F3F4F6F7F85,586$366.9922$2.05M1,954,462IndirectSee Footnotes
PurchaseNov 4, 2026
Common StockF9F2F3F4F6F7F810,080$368.1134$3.71M1,964,542IndirectSee Footnotes
Filing footnotes · 9
  1. F1As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  2. F2Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
  3. F3Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  4. F4Includes beneficial ownership of 3,825 shares of Common Stock received from vested restricted stock units of the Issuer (each an "RSU") and 454 shares of Common Stock underlying unvested RSUs previously granted to each of Julian C. Baker, a managing member of the Adviser GP, and Dr. Raymond Cheong, a full-time employee of the Adviser, in their capacity as directors of the Issuer.
  5. F5The price reported in Column 4 is a weighted average price. These shares of Common Stock were traded by Life Sciences in multiple transactions at prices ranging from $366.77 to $367.17, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  6. F6Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the non-qualified stock options exercisable solely into Common Stock ("Stock Options"), RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
  7. F7Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the board of directors of the Issuer and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Stock Options and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such service on the board of directors of the Issuer.
  8. F8After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
  9. F9The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $367.41 to $368.30, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
William John SiboldDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Sep 11, 2026Period of report Sep 9, 20260001628280-26-061581
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 11, 2026
Common StockF16F1760$533.0913$31.99K202,907Direct
SaleSep 11, 2026
Common StockF16F18106$534.063$56.61K202,801Direct
SaleSep 11, 2026
Common StockF16F19218$535.9435$116.84K202,583Direct
SaleSep 11, 2026
Common StockF16F20160$537.6175$86.02K202,423Direct
SaleSep 11, 2026
Common StockF16F21687$540.5857$371.38K201,736Direct
SaleSep 11, 2026
Common StockF16F22368$541.6423$199.32K201,368Direct
SaleSep 11, 2026
Common StockF16F231,202$542.6032$652.21K200,166Direct
SaleSep 11, 2026
Common StockF16F241,539$544.024$837.25K198,627Direct
SaleSep 11, 2026
Common StockF16F25761$544.8307$414.62K197,866Direct
SaleSep 11, 2026
Common StockF16F26120$546.3767$65.57K197,746Direct
SaleSep 9, 2026
Common StockF1F2131$527.8783$69.15K209,198Direct
SaleSep 9, 2026
Common StockF1F3347$529.2671$183.66K208,851Direct
SaleSep 9, 2026
Common StockF1F4522$530.2311$276.78K208,329Direct
SaleSep 9, 2026
Common StockF1F5368$531.9897$195.77K207,961Direct
SaleSep 9, 2026
Common StockF1F6512$533.0932$272.94K207,449Direct
SaleSep 9, 2026
Common StockF1F7396$534.1964$211.54K207,053Direct
SaleSep 9, 2026
Common StockF1F8644$535.2719$344.72K206,409Direct
SaleSep 9, 2026
Common StockF1F91,040$536.1123$557.56K205,369Direct
SaleSep 9, 2026
Common StockF1F10640$537.1738$343.79K204,729Direct
SaleSep 9, 2026
Common StockF1F11520$538.2971$279.91K204,209Direct
SaleSep 9, 2026
Common StockF1F12215$539.0281$115.89K203,994Direct
SaleSep 9, 2026
Common StockF1F13505$540.1909$272.80K203,489Direct
SaleSep 9, 2026
Common StockF1F14362$541.6538$196.08K203,127Direct
SaleSep 9, 2026
Common StockF1F15160$542.5475$86.81K202,967Direct
Filing footnotes · 26
  1. F1This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
  2. F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $536.64 to $537.56, inclusive.
  3. F11The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.70 to $538.65, inclusive.
  4. F12The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $538.86 to $539.83, inclusive.
  5. F13The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.86 to $540.47, inclusive.
  6. F14The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.29 to $542.27, inclusive.
  7. F15The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.42 to $542.68, inclusive.
  8. F16These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026.
  9. F17The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.76 to $533.64, inclusive.
  10. F18The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.76 to $534.48, inclusive.
  11. F19The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.52 to $536.02, inclusive.
  12. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.49 to $528.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
  13. F20The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.235 to $538.00, inclusive.
  14. F21The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.97 to $540.90, inclusive.
  15. F22The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.00 to $541.73, inclusive.
  16. F23The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.11 to $543.02, inclusive.
  17. F24The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $543.27 to $544.20, inclusive.
  18. F25The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $544.38 to $545.32, inclusive.
  19. F26The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $546.28 to $546.56, inclusive.
  20. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.54 to $529.51, inclusive.
  21. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $529.64 to $530.48, inclusive.
  22. F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $531.57 to $532.28, inclusive.
  23. F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.57 to $533.29, inclusive.
  24. F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.58 to $534.57, inclusive.
  25. F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $534.63 to $535.62, inclusive.
  26. F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.64 to $536.45, inclusive.
Open on SEC EDGAR
Shannon T KelleyGeneral Counsel
4
Filed Aug 20, 2026Period of report Aug 17, 20260001628280-26-058256
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 17, 2026
Common StockF1664$514.97$341.94K11,474Direct
Filing footnotes · 1
  1. F1This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
Open on SEC EDGAR
William John SiboldDirector · President and CEO
4
Filed Jul 20, 2026Period of report Jul 17, 20260001628280-26-048919
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 20, 2026
Common StockF2F3140$542.7459$75.98K211,689Direct
SaleJul 20, 2026
Common StockF2F4110$543.7929$59.82K211,579Direct
SaleJul 20, 2026
Common StockF2F5545$544.714$296.87K211,034Direct
SaleJul 20, 2026
Common StockF2F6275$545.7092$150.07K210,759Direct
SaleJul 20, 2026
Common StockF2F7269$547.0788$147.16K210,490Direct
SaleJul 20, 2026
Common StockF2F8680$547.698$372.43K209,810Direct
SaleJul 20, 2026
Common StockF2F947$548.8719$25.80K209,763Direct
SaleJul 20, 2026
Common StockF2F10153$550.0138$84.15K209,610Direct
SaleJul 20, 2026
Common StockF21$550.72$550.72209,609Direct
SaleJul 20, 2026
Common StockF2F11280$555.05$155.41K209,329Direct
Filing footnotes · 12
  1. F1On July 17, 2026, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 12. Pursuant to the terms of the award, certain of these shares were sold to cover certain tax withholding obligations as described in Footnote 2 below. The Issuer is irrevocably obligated to issue the remaining shares to the Reporting Person on September 8, 2029, the sixth anniversary of the commencement of his employment with the Issuer.
  2. F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $549.70 to $550.24, inclusive.
  3. F11The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $555.00 to $555.10, inclusive.
  4. F12On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that could be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person was eligible to earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025, the second hurdle in December 2025 and the third and final hurdle reported on this line, all performance hurdles have been achieved. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units.
  5. F2The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person.
  6. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.22 to $543.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
  7. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $543.26 to $544.25, inclusive.
  8. F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $544.31 to $545.28, inclusive.
  9. F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $545.31 to $546.29, inclusive.
  10. F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $546.37 to $547.35, inclusive.
  11. F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $547.40 to $548.29, inclusive.
  12. F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $548.42 to $549.39, inclusive.
Open on SEC EDGAR
David SoergelChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Jun 1, 2026Period of report Jun 1, 20260001628280-26-039653
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 1, 2026
Common StockF11,042$495.74$516.56K10,033Direct
Filing footnotes · 1
  1. F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.
Open on SEC EDGAR
Richard S LevyDirector
4Rule 10b5-1 plan disclosed
Filed May 22, 2026Period of report May 22, 20260001628280-26-037830
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 22, 2026
Common StockF1F240$506.675$20.27K27,657Direct
SaleMay 22, 2026
Common StockF1F3320$508.242$162.64K27,337Direct
SaleMay 22, 2026
Common StockF1F4151$510.3579$77.06K27,186Direct
SaleMay 22, 2026
Common StockF1F5610$511.3967$311.95K26,576Direct
SaleMay 22, 2026
Common StockF1F6439$512.5022$224.99K26,137Direct
SaleMay 22, 2026
Common StockF140$512.97$20.52K26,097Direct
SaleMay 22, 2026
Common StockF1F7343$514.6691$176.53K25,754Direct
SaleMay 22, 2026
Common StockF1F8657$515.9219$338.96K25,097Direct
SaleMay 22, 2026
Common StockF1F9723$516.8658$373.69K24,374Direct
SaleMay 22, 2026
Common StockF1F101,497$517.5921$774.84K22,877Direct
SaleMay 22, 2026
Common StockF1F11782$518.758$405.67K22,095Direct
SaleMay 22, 2026
Common StockF1F1280$519.98$41.60K22,015Direct
Filing footnotes · 12
  1. F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2026.
  2. F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.28 to $518.27, inclusive.
  3. F11The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.30 to $519.29, inclusive.
  4. F12The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.68 to $520.28, inclusive.
  5. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.42 to $507.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
  6. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $508.11 to $508.89, inclusive.
  7. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $509.89 to $510.85, inclusive.
  8. F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $510.89 to $511.87, inclusive.
  9. F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $511.91 to $512.88, inclusive.
  10. F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.17 to $515.16, inclusive.
  11. F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.26 to $516.22, inclusive.
  12. F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $516.28 to $517.27, inclusive.
Open on SEC EDGAR
David SoergelChief Medical Officer
4
Filed May 18, 2026Period of report May 18, 20260001628280-26-036078
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 18, 2026
Common StockF1844$515.90$435.42K11,075Direct
Filing footnotes · 1
  1. F1This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
Open on SEC EDGAR
Mardi DierEVP and CFO
4Rule 10b5-1 plan disclosed
Filed Mar 6, 2026Period of report Mar 4, 20260001628280-26-015775
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 6, 2026
Common StockF2646$431.94$279.03K13,826Direct
SaleMar 6, 2026
Common StockF340$425.08$17.00K13,786Direct
SaleMar 6, 2026
Common StockF3F4420$426.8638$179.28K13,366Direct
SaleMar 6, 2026
Common StockF3F580$427.845$34.23K13,286Direct
SaleMar 6, 2026
Common StockF3F6160$428.995$68.64K13,126Direct
SaleMar 6, 2026
Common StockF340$429.58$17.18K13,086Direct
SaleMar 6, 2026
Common StockF3F7120$430.9033$51.71K12,966Direct
SaleMar 6, 2026
Common StockF3F8116$432.5559$50.18K12,850Direct
SaleMar 6, 2026
Common StockF3F9160$434.20$69.47K12,690Direct
SaleMar 6, 2026
Common StockF3F1080$435.315$34.83K12,610Direct
SaleMar 6, 2026
Common StockF3F1180$436.69$34.94K12,530Direct
SaleMar 6, 2026
Common StockF340$437.65$17.51K12,490Direct
Filing footnotes · 12
  1. F1Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.
  2. F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $435.26 to $435.37, inclusive.
  3. F11The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $436.46 to $436.92, inclusive.
  4. F12The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
  5. F2This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
  6. F3These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025.
  7. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $426.46 to $427.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
  8. F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $427.50 to $428.19, inclusive.
  9. F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $428.51 to $429.24, inclusive.
  10. F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $430.66 to $431.04, inclusive.
  11. F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $432.41 to $432.99, inclusive.
  12. F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $433.82 to $434.58, inclusive.
Open on SEC EDGAR
William John SiboldDirector · President and CEO
4
Filed Mar 6, 2026Period of report Mar 4, 20260001628280-26-015769
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 6, 2026
Common StockF21,663$431.94$718.32K161,829Direct
Filing footnotes · 3
  1. F1Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.
  2. F2This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
  3. F3The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
Open on SEC EDGAR
Shannon T KelleyGeneral Counsel
4
Filed Mar 6, 2026Period of report Mar 4, 20260001628280-26-015763
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 6, 2026
Common StockF2360$431.94$155.50K12,138Direct
Filing footnotes · 3
  1. F1Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.
  2. F2This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
  3. F3The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
Open on SEC EDGAR
Carole HuntsmanChief Commercial Officer
4
Filed Mar 6, 2026Period of report Mar 4, 20260001628280-26-015758
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 6, 2026
Common StockF2419$431.94$180.98K12,692Direct
Filing footnotes · 3
  1. F1Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.
  2. F2This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
  3. F3The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
Open on SEC EDGAR
Rebecca TaubDirector
4
Filed Mar 6, 2026Period of report Mar 6, 20260001628280-26-015736
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 6, 2026
Common StockF1491$431.94$212.08K452,213Direct
Filing footnotes · 2
  1. F1This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
  2. F2The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
Mardi DierEVP and CFO
4
Filed Mar 2, 2026Period of report Mar 2, 20260001628280-26-013394
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF11,183$427.21$505.39K9,257Direct
Filing footnotes · 1
  1. F1This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
Open on SEC EDGAR
Carole HuntsmanChief Commercial Officer
4Rule 10b5-1 plan disclosed
Filed Jan 26, 2026Period of report Jan 26, 20260001628280-26-003482
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 26, 2026
Common StockF1340$492.42$167.42K9,692Direct
SaleJan 26, 2026
Common StockF2570$494.59$281.92K9,122Direct
Filing footnotes · 2
  1. F1The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
  2. F2This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.
Open on SEC EDGAR
William John SiboldDirector · President and CEO
4
Filed Jan 26, 2026Period of report Jan 26, 20260001628280-26-003468
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 26, 2026
Common StockF11,577$492.42$776.55K148,497Direct
Filing footnotes · 1
  1. F1This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
Open on SEC EDGAR
Rebecca TaubDirector
4
Filed Jan 26, 2026Period of report Jan 26, 20260001628280-26-003452
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 26, 2026
Common StockF1647$492.42$318.60K452,704Direct
Filing footnotes · 2
  1. F1This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
  2. F2The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
Shannon T KelleyGeneral Counsel
4Rule 10b5-1 plan disclosed
Filed Jan 20, 2026Period of report Jan 20, 20260001628280-26-002742
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 20, 2026
Common StockF1263$490.77$129.07K8,910Direct
SaleJan 20, 2026
Common StockF2429$501.40$215.10K8,481Direct
Filing footnotes · 2
  1. F1This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
  2. F2This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024.
Open on SEC EDGAR
Rebecca TaubDirector
4
Filed Jan 20, 2026Period of report Jan 20, 20260001628280-26-002735
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 20, 2026
Common StockF12,238$490.77$1.10M453,351Direct
Filing footnotes · 2
  1. F1This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
  2. F2The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
Paul a FriedmanDirector
4Rule 10b5-1 plan disclosed
Filed Jan 13, 2026Period of report Jan 9, 20260001628280-26-001981
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 9, 2026
Common StockF1F2280$551.2414$154.35K187,164Direct
Filing footnotes · 4
  1. F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.24 to $551.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  4. F4The shares underlying this stock option are fully vested and exercisable.
Open on SEC EDGAR
Paul a FriedmanDirector
4Rule 10b5-1 plan disclosed
Filed Jan 13, 2026Period of report Jan 9, 20260001628280-26-001976
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 9, 2026
Common StockF1F21,480$511.9774$757.73K210,204Direct
SaleJan 9, 2026
Common StockF1F31,094$513.1079$561.34K209,110Direct
SaleJan 9, 2026
Common StockF1F41,345$514.681$692.25K207,765Direct
SaleJan 9, 2026
Common StockF1F51,996$515.8123$1.03M205,769Direct
SaleJan 9, 2026
Common StockF1F6766$516.8356$395.90K205,003Direct
SaleJan 9, 2026
Common StockF1F72,450$517.8591$1.27M202,553Direct
SaleJan 9, 2026
Common StockF1F81,363$518.6837$706.97K201,190Direct
SaleJan 9, 2026
Common StockF1F9846$519.8838$439.82K200,344Direct
SaleJan 9, 2026
Common StockF1F10681$521.0327$354.82K199,663Direct
SaleJan 9, 2026
Common StockF1F11840$521.9779$438.46K198,823Direct
SaleJan 9, 2026
Common StockF1F12970$522.9972$507.31K197,853Direct
SaleJan 9, 2026
Common StockF1F131,199$524.0986$628.39K196,654Direct
SaleJan 9, 2026
Common StockF1F142,432$525.0475$1.28M194,222Direct
SaleJan 9, 2026
Common StockF1F151,066$526.0005$560.72K193,156Direct
SaleJan 9, 2026
Common StockF1F161,560$526.9685$822.07K191,596Direct
SaleJan 9, 2026
Common StockF1F17575$528.1777$303.70K191,021Direct
SaleJan 9, 2026
Common StockF1F18691$529.1654$365.65K190,330Direct
SaleJan 9, 2026
Common StockF1F19166$529.7624$87.94K190,164Direct
SaleJan 9, 2026
Common StockF1F20280$530.6871$148.59K189,884Direct
SaleJan 9, 2026
Common StockF180$532.50$42.60K189,804Direct
SaleJan 9, 2026
Common StockF1F21332$534.1638$177.34K189,472Direct
SaleJan 9, 2026
Common StockF1F22148$535.2886$79.22K189,324Direct
SaleJan 9, 2026
Common StockF1F23473$536.0206$253.54K188,851Direct
SaleJan 9, 2026
Common StockF1F24487$536.8768$261.46K188,364Direct
SaleJan 9, 2026
Common StockF1F2580$537.845$43.03K188,284Direct
SaleJan 9, 2026
Common StockF1F26480$539.2317$258.83K187,804Direct
SaleJan 9, 2026
Common StockF1F27600$540.358$324.21K187,204Direct
SaleJan 9, 2026
Common StockF140$545.79$21.83K187,164Direct
Filing footnotes · 29
  1. F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025.
  2. F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $520.48 to $521.45, inclusive.
  3. F11The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $521.49 to $522.40, inclusive.
  4. F12The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $522.49 to $523.46, inclusive.
  5. F13The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $523.51 to $524.48, inclusive.
  6. F14The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $524.51 to $525.49, inclusive.
  7. F15The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $525.55 to $526.50, inclusive.
  8. F16The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $526.56 to $527.51, inclusive.
  9. F17The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.56 to $528.53, inclusive.
  10. F18The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.56 to $529.52, inclusive.
  11. F19The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $529.56 to $530.12, inclusive.
  12. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $511.71 to $512.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
  13. F20The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $530.63 to $531.03, inclusive.
  14. F21The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.60 to $534.54, inclusive.
  15. F22The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $534.60 to $535.57, inclusive.
  16. F23The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.62 to $536.57, inclusive.
  17. F24The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $536.64 to $537.11, inclusive.
  18. F25The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.83 to $537.86, inclusive.
  19. F26The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.00 to $539.42, inclusive.
  20. F27The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $540.25 to $540.38, inclusive.
  21. F28The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  22. F29The shares underlying this stock option are fully vested and exercisable.
  23. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $512.77 to $513.60, inclusive.
  24. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.28 to $515.22, inclusive.
  25. F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.29 to $516.21, inclusive.
  26. F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $516.34 to $517.28, inclusive.
  27. F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.36 to $518.35, inclusive.
  28. F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.38 to $519.37, inclusive.
  29. F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.45 to $520.42, inclusive.
Open on SEC EDGAR
Rebecca TaubDirector
4Rule 10b5-1 plan disclosed
Filed Jan 13, 2026Period of report Jan 9, 20260001628280-26-001970
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 9, 2026
Common StockF140$545.79$21.83K455,789Direct
SaleJan 9, 2026
Common StockF1F2200$551.242$110.25K455,589Direct
Filing footnotes · 4
  1. F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.24 to $551.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  4. F4The shares underlying this stock option are fully vested and exercisable.
Open on SEC EDGAR
Rebecca TaubDirector
4Rule 10b5-1 plan disclosed
Filed Jan 13, 2026Period of report Jan 9, 20260001628280-26-001961
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 9, 2026
Common StockF1F2960$512.0179$491.54K473,039Direct
SaleJan 9, 2026
Common StockF1F3960$513.1196$492.59K472,079Direct
SaleJan 9, 2026
Common StockF1F4937$514.6291$482.21K471,142Direct
SaleJan 9, 2026
Common StockF1F51,578$515.8228$813.97K469,564Direct
SaleJan 9, 2026
Common StockF1F6521$516.8085$269.26K469,043Direct
SaleJan 9, 2026
Common StockF1F72,044$517.8415$1.06M466,999Direct
SaleJan 9, 2026
Common StockF1F8970$518.6658$503.11K466,029Direct
SaleJan 9, 2026
Common StockF1F9539$519.8879$280.22K465,490Direct
SaleJan 9, 2026
Common StockF1F10440$521.1112$229.29K465,050Direct
SaleJan 9, 2026
Common StockF1F11588$521.9535$306.91K464,462Direct
SaleJan 9, 2026
Common StockF1F12732$522.9817$382.82K463,730Direct
SaleJan 9, 2026
Common StockF1F131,335$524.062$699.62K462,395Direct
SaleJan 9, 2026
Common StockF1F141,489$525.1196$781.90K460,906Direct
SaleJan 9, 2026
Common StockF1F15913$526.0475$480.28K459,993Direct
SaleJan 9, 2026
Common StockF1F161,135$526.9523$598.09K458,858Direct
SaleJan 9, 2026
Common StockF1F17465$528.1562$245.59K458,393Direct
SaleJan 9, 2026
Common StockF1F18554$529.2813$293.22K457,839Direct
SaleJan 9, 2026
Common StockF1F19256$530.4525$135.80K457,583Direct
SaleJan 9, 2026
Common StockF130$531.05$15.93K457,553Direct
SaleJan 9, 2026
Common StockF140$532.50$21.30K457,513Direct
SaleJan 9, 2026
Common StockF1F20271$534.1751$144.76K457,242Direct
SaleJan 9, 2026
Common StockF1F2189$534.9324$47.61K457,153Direct
SaleJan 9, 2026
Common StockF1F22299$535.8041$160.21K456,854Direct
SaleJan 9, 2026
Common StockF1F23385$536.8832$206.70K456,469Direct
SaleJan 9, 2026
Common StockF140$537.84$21.51K456,429Direct
SaleJan 9, 2026
Common StockF1F24400$539.264$215.71K456,029Direct
SaleJan 9, 2026
Common StockF140$540.26$21.61K455,989Direct
SaleJan 9, 2026
Common StockF1400$542.72$217.09K455,589Direct
Filing footnotes · 26
  1. F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025.
  2. F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $520.46 to $521.45, inclusive.
  3. F11The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $521.50 to $522.49, inclusive.
  4. F12The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $522.51 to $523.47, inclusive.
  5. F13The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $523.59 to $524.58, inclusive.
  6. F14The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $524.59 to $525.56, inclusive.
  7. F15The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $525.59 to $526.55, inclusive.
  8. F16The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $526.63 to $527.58, inclusive.
  9. F17The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.71 to $528.52, inclusive.
  10. F18The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.72 to $529.69, inclusive.
  11. F19The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $529.97 to $530.63, inclusive.
  12. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $511.71 to $512.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
  13. F20The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.60 to $534.57, inclusive.
  14. F21The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $534.60 to $534.99, inclusive.
  15. F22The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.62 to $536.32, inclusive.
  16. F23The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $536.64 to $537.30, inclusive.
  17. F24The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.00 to $539.44, inclusive.
  18. F25The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  19. F26The shares underlying this stock option are fully vested and exercisable.
  20. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.00 to $513.58, inclusive.
  21. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.32 to $515.25, inclusive.
  22. F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.32 to $516.29, inclusive.
  23. F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $516.32 to $517.26, inclusive.
  24. F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.36 to $518.35, inclusive.
  25. F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.39 to $519.29, inclusive.
  26. F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.45 to $520.38, inclusive.
Open on SEC EDGAR
Paul a FriedmanDirector
4Rule 10b5-1 plan disclosed
Filed Dec 12, 2025Period of report Dec 10, 20250001628280-25-056794
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 10, 2025
Common StockF1F2624$547.7462$341.79K211,340Direct
SaleDec 10, 2025
Common StockF1F3535$548.5067$293.45K210,805Direct
SaleDec 10, 2025
Common StockF1F4409$549.9871$224.94K210,396Direct
SaleDec 10, 2025
Common StockF1F54,316$550.9328$2.38M206,080Direct
SaleDec 10, 2025
Common StockF1F67,193$551.6653$3.97M198,887Direct
SaleDec 10, 2025
Common StockF1F75,533$552.7439$3.06M193,354Direct
SaleDec 10, 2025
Common StockF1F85,001$553.8349$2.77M188,353Direct
SaleDec 10, 2025
Common StockF1F91,029$554.9963$571.09K187,324Direct
SaleDec 10, 2025
Common StockF1160$555.39$88.86K187,164Direct
Filing footnotes · 11
  1. F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025.
  2. F10The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  3. F11The shares underlying this stock option are fully vested and exercisable.
  4. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $547.17 to $548.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
  5. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $548.17 to $549.08, inclusive.
  6. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $549.27 to $550.23, inclusive.
  7. F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $550.28 to $551.26, inclusive.
  8. F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.28 to $552.26, inclusive.
  9. F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $552.28 to $553.27, inclusive.
  10. F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $553.28 to $554.27, inclusive.
  11. F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $554.39 to $555.31, inclusive.
Open on SEC EDGAR
Rebecca TaubDirector
4Rule 10b5-1 plan disclosed
Filed Dec 12, 2025Period of report Dec 10, 20250001628280-25-056792
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 10, 2025
Common StockF1F2491$547.7567$268.95K479,203Direct
SaleDec 10, 2025
Common StockF1F3369$548.5579$202.42K478,834Direct
SaleDec 10, 2025
Common StockF1F4486$550.0715$267.33K478,348Direct
SaleDec 10, 2025
Common StockF1F54,723$550.9861$2.60M473,625Direct
SaleDec 10, 2025
Common StockF1F64,410$551.8461$2.43M469,215Direct
SaleDec 10, 2025
Common StockF1F73,857$552.8122$2.13M465,358Direct
SaleDec 10, 2025
Common StockF1F83,087$553.8795$1.71M462,271Direct
SaleDec 10, 2025
Common StockF1F91,027$554.8417$569.82K461,244Direct
SaleDec 10, 2025
Common StockF1200$555.39$111.08K461,044Direct
Filing footnotes · 12
  1. F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025.
  2. F10The Reporting Person made a charitable contribution of 5,455 shares of common stock of the Issuer to a donor advised fund.
  3. F11The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  4. F12The shares underlying this stock option are fully vested and exercisable.
  5. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $547.16 to $548.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
  6. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $548.17 to $549.00, inclusive.
  7. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $549.38 to $550.37, inclusive.
  8. F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $550.39 to $551.38, inclusive.
  9. F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.39 to $552.38, inclusive.
  10. F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $552.39 to $553.38, inclusive.
  11. F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $553.39 to $554.33, inclusive.
  12. F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $554.39 to $555.31, inclusive.
Open on SEC EDGAR
William John SiboldDirector · President and CEO
4
Filed Dec 4, 2025Period of report Dec 3, 20250001628280-25-055430
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 4, 2025
Common StockF22,400$575.34$1.38M150,074Direct
Filing footnotes · 3
  1. F1On December 3, 2025, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 3. Pursuant to the terms of the award, certain of these shares were sold to cover certain tax withholding obligations as described in Footnote 2 below. The Issuer is irrevocably obligated to issue the remaining shares to the Reporting Person on September 8, 2028, the fifth anniversary of the commencement of his employment with the Issuer.
  2. F2The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person.
  3. F3On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025 and the second hurdle reported on this line, the Reporting Person is eligible to earn an additional 50,000 shares upon the achievement of the final performance hurdle. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units.
Open on SEC EDGAR
Mardi DierEVP and CFO
4Rule 10b5-1 plan disclosed
Filed Dec 3, 2025Period of report Dec 2, 20250001628280-25-055164
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 2, 2025
Common StockF1F2320$570.386$182.52K14,293Direct
SaleDec 2, 2025
Common StockF1F3410$571.9892$234.52K13,883Direct
SaleDec 2, 2025
Common StockF1F4354$573.0151$202.85K13,529Direct
SaleDec 2, 2025
Common StockF1F5717$574.0011$411.56K12,812Direct
SaleDec 2, 2025
Common StockF1F6120$574.9524$68.99K12,692Direct
SaleDec 2, 2025
Common StockF1F7240$576.1517$138.28K12,452Direct
SaleDec 2, 2025
Common StockF1F8320$577.8144$184.90K12,132Direct
SaleDec 2, 2025
Common StockF1F9258$578.831$149.34K11,874Direct
SaleDec 2, 2025
Common StockF1F10480$579.8525$278.33K11,394Direct
SaleDec 2, 2025
Common StockF1F11240$585.4383$140.51K11,154Direct
SaleDec 2, 2025
Common StockF1F12240$587.8495$141.08K10,914Direct
SaleDec 2, 2025
Common StockF1F13160$589.6479$94.34K10,754Direct
SaleDec 2, 2025
Common StockF1F14160$590.3725$94.46K10,594Direct
SaleDec 2, 2025
Common StockF1F1574$595.2047$44.05K10,520Direct
SaleDec 2, 2025
Common StockF1F1680$596.185$47.69K10,440Direct
Filing footnotes · 17
  1. F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025.
  2. F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.59 to $580.46, inclusive.
  3. F11The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.08 to $585.99, inclusive.
  4. F12The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.58 to $588.07, inclusive.
  5. F13The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.13 to $589.96, inclusive.
  6. F14The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.15 to $590.58, inclusive.
  7. F15The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $595.18 to $595.41, inclusive.
  8. F16The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $596.18 to $596.19, inclusive.
  9. F17All shares issued pursuant to the exercise of the options reported herein represent 4,173 shares underlying an overall option award of 13,353 shares. All exercised options had vested. As to the overall option for 13,353 shares, 25% of the shares vested on March 1, 2025, and, thereafter, 6.25% of the shares vested or will vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
  10. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.17 to $570.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
  11. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.45 to $572.34, inclusive.
  12. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.48 to $573.38, inclusive.
  13. F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.59 to $574.44, inclusive.
  14. F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.67 to $575.24, inclusive.
  15. F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.69 to $576.46, inclusive.
  16. F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.36 to $578.31, inclusive.
  17. F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $578.37 to $579.20, inclusive.
Open on SEC EDGAR
Carole HuntsmanChief Commercial Officer
4Rule 10b5-1 plan disclosed
Filed Nov 21, 2025Period of report Nov 21, 20250001628280-25-053648
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 21, 2025
Common StockF1894$550.97$492.57K11,096Direct
SaleNov 21, 2025
Common StockF2F3144$547.2683$78.81K10,952Direct
SaleNov 21, 2025
Common StockF2F4120$548.71$65.85K10,832Direct
SaleNov 21, 2025
Common StockF2F540$549.3425$21.97K10,792Direct
SaleNov 21, 2025
Common StockF2F6200$552.384$110.48K10,592Direct
SaleNov 21, 2025
Common StockF2F740$553.2283$22.13K10,552Direct
SaleNov 21, 2025
Common StockF2F8120$556.04$66.72K10,432Direct
SaleNov 21, 2025
Common StockF2F9200$559.598$111.92K10,232Direct
SaleNov 21, 2025
Common StockF2F1080$560.62$44.85K10,152Direct
SaleNov 21, 2025
Common StockF240$563.21$22.53K10,112Direct
SaleNov 21, 2025
Common StockF2F1180$564.565$45.17K10,032Direct
Filing footnotes · 11
  1. F1The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
  2. F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $560.24 to $561.00, inclusive.
  3. F11The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $564.55 to $564.58, inclusive.
  4. F2These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.
  5. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $547.12 to $547.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
  6. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $548.25 to $548.94, inclusive.
  7. F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $549.30 to $549.38, inclusive.
  8. F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.96 to $552.81, inclusive.
  9. F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $553.22 to $553.23, inclusive.
  10. F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $555.74 to $556.19, inclusive.
  11. F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $559.22 to $560.06, inclusive.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.